Literature DB >> 2869974

Somatostatin and alpha 2-adrenergic agonists selectively inhibit vasopressin-induced cyclic AMP accumulation in MDCK cells.

G Friedlander, C Amiel.   

Abstract

The effect of somatostatin and alpha 2-adrenergic agonists on cyclic AMP accumulation was examined in MDCK cells, grown in defined medium. These hormones inhibited vasopressin-induced cyclic AMP formation, without affecting either the basal or the glucagon- and prostaglandin E2-stimulated level. Pretreating the cells with pertussis toxin, or incubating them with MnCl2 at a low concentration reversed the effect of somatostatin and alpha 2-agonists. These results suggest that somatostatin and norepinephrine could selectively modulate the renal effect of vasopressin, via the inhibitory regulatory subunit (Ni) of adenylate cyclase.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2869974     DOI: 10.1016/0014-5793(86)81180-2

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  13 in total

1.  Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.

Authors:  Marie C Hogan; Tetyana V Masyuk; Linda J Page; Vickie J Kubly; Eric J Bergstralh; Xujian Li; Bohyun Kim; Bernard F King; James Glockner; David R Holmes; Sandro Rossetti; Peter C Harris; Nicholas F LaRusso; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2010-04-29       Impact factor: 10.121

Review 2.  Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2013-12-12       Impact factor: 10.121

3.  Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.

Authors:  Esther Meijer; Folkert W Visser; Rene M M van Aerts; Charles J Blijdorp; Niek F Casteleijn; Hedwig M A D'Agnolo; Shosha E I Dekker; Joost P H Drenth; Johan W de Fijter; Maatje D A van Gastel; Tom J Gevers; Marten A Lantinga; Monique Losekoot; A Lianne Messchendorp; Myrte K Neijenhuis; Michelle J Pena; Dorien J M Peters; Mahdi Salih; Darius Soonawala; Edwin M Spithoven; Jack F Wetzels; Robert Zietse; Ron T Gansevoort
Journal:  JAMA       Date:  2018-11-20       Impact factor: 56.272

4.  Antidiuretic hormone stimulation of adenylate cyclase in semicircular canal epithelium.

Authors:  E Ferrary; C Bernard; G Friedlander; O Sterkers; C Amiel
Journal:  Eur Arch Otorhinolaryngol       Date:  1991       Impact factor: 2.503

Review 5.  Novel therapeutic approaches to autosomal dominant polycystic kidney disease.

Authors:  Wells B LaRiviere; Maria V Irazabal; Vicente E Torres
Journal:  Transl Res       Date:  2014-11-13       Impact factor: 7.012

6.  Safety study of somatostatin analogue octreotide for autosomal dominant polycystic kidney disease in Japan.

Authors:  Eiji Higashihara; Kikuo Nutahara; Takatsugu Okegawa; Mitsuhiro Tanbo; Hideaki Mori; Isao Miyazaki; Toshiaki Nitatori; Kuninori Kobayashi
Journal:  Clin Exp Nephrol       Date:  2014-10-29       Impact factor: 2.801

7.  VX-809 mitigates disease in a mouse model of autosomal dominant polycystic kidney disease bearing the R3277C human mutation.

Authors:  Murali K Yanda; Liudmila Cebotaru
Journal:  FASEB J       Date:  2021-11       Impact factor: 5.834

Review 8.  Rare cystic liver lesions: a diagnostic and managing challenge.

Authors:  Andreas Bakoyiannis; Spiros Delis; Charina Triantopoulou; Christos Dervenis
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

9.  Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model.

Authors:  Katharina Hopp; Cynthia J Hommerding; Xiaofang Wang; Hong Ye; Peter C Harris; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2014-07-03       Impact factor: 10.121

Review 10.  Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling.

Authors:  Caroline R Sussman; Xiaofang Wang; Fouad T Chebib; Vicente E Torres
Journal:  Cell Signal       Date:  2020-04-23       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.